Lost miR-141 and upregulated TM4SF1 expressions associate with poor prognosis of pancreatic cancer: regulation of EMT and angiogenesis by miR-141 and TM4SF1 via AKT

References

• Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet (London, England). 2012;380:2095–2128. doi:10.1016/S0140-6736(12)61728-0.
   PubMed Web of Science ®Google Scholar
• Organization WH. World cancer report 2014. Pancreatic Cancer. 2014:413–421.
   Google Scholar
• Bond-Smith G, Banga N, Hammond TM, Imber CJ. Pancreatic adenocarcinoma. BMJ. 2012;344:e2476.
   PubMed Web of Science ®Google Scholar
• Wolfgang CL, Herman JM, Laheru DA, Klein AP, Erdek MA, Fishman EK, Hruban RH. Recent progress in pancreatic cancer. CA Cancer J Clin. 2013;63:318–348.
   PubMed Web of Science ®Google Scholar
• Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014;371:2140–2141. doi:10.1056/NEJMra1404198.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182–1186.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002;29:10–14. doi:10.1053/sonc.2002.37264.
   PubMed Web of Science ®Google Scholar
• Ellis LM, Rosen L, Gordon MS. Overview of anti-vegf therapy and angiogenesis. Part 1: angiogenesis inhibition in solid tumor malignancies. Clin Adv Hematol Oncol. 2006;4(suppl):1–10; quz 11-2.
   Google Scholar
• Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase iii clinical trials on anti-vegf therapy for cancer. Nat Clin Pract Oncol. 2006;3:24–40.
   PubMedGoogle Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. doi:10.1056/NEJMoa032691.
   PubMed Web of Science ®Google Scholar
• Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. Emt: present and future in clinical oncology. Mol Oncol. 2017;11:718–738.
   PubMed Web of Science ®Google Scholar
• Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21–45.
   PubMed Web of Science ®Google Scholar
• Zukauskas A, Merley A, Li D, Ang LH, Sciuto TE, Salman S, Dvorak AM, Dvorak HF, Jaminet SC. Tm4sf1: a tetraspanin-like protein necessary for nanopodia formation and endothelial cell migration. Angiogenesis. 2011;14:345–354.
   PubMed Web of Science ®Google Scholar
• Lin CI, Merley A, Sciuto TE, Li D, Dvorak AM, Melero-Martin JM, Dvorak HF, Jaminet SC. Tm4sf1: a new vascular therapeutic target in cancer. Angiogenesis. 2014;17:897–907.
   PubMed Web of Science ®Google Scholar
• Park YR, Kim SL, Lee MR, Seo SY, Lee JH, Kim SH, Kim IH, Lee SO, Lee ST, Kim SW, et al. Microrna-30a-5p (mir-30a) regulates cell motility and emt by directly targeting oncogenic TM4SF1 in colorectal cancer. J Cancer Res Clin Oncol. 2017;143:1915–1927. doi:10.1007/s00432-017-2440-4.
   PubMed Web of Science ®Google Scholar
• Hellstrom I, Horn D, Linsley P, Brown JP, Brankovan V, Hellström KE. Monoclonal mouse antibodies raised against human lung carcinoma. Cancer Res. 1986;46:3917–3923.
   PubMed Web of Science ®Google Scholar
• Marken JS, Schieven GL, Hellstrom I, Hellström KE, Aruffo A. Cloning and expression of the tumor-associated antigen l6. Proc Natl Acad Sci U S A. 1992;89:3503–3507.
   PubMed Web of Science ®Google Scholar
• Kao YR, Shih JY, Wen WC, Ko Y-P, Chen B-M, Chan Y-L, Chu Y-W, Yang P-C, Wu C-W, Roffler SR, et al. Tumor-associated antigen l6 and the invasion of human lung cancer cells. Clin Cancer Res. 2003;9:2807–2816.
   PubMed Web of Science ®Google Scholar
• Lin CI, Lau CY, Li D, Jaminet SC. et al. Nanopodia–thin, fragile membrane projections with roles in cell movement and intercellular interactions. J Visualized Exp. 2014;86.
   Google Scholar
• Xu L, Li Q, Xu D, Wang Q, An Y, Du Q, Zhang J, Zhu Y, Miao Y. Hsa-mir-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Int J Oncol. 2014;44:459–466.
   PubMed Web of Science ®Google Scholar
• Bartel DP. Micrornas: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–297. doi:10.1016/S0092-8674(04)00045-5.
   PubMed Web of Science ®Google Scholar
• Hruban R, Klöppel G, Boffetta P. Ductal adenocarcinoma of the pancreas. In: The International Agency for Research on Cancer, Carneiro F, Hruban RH, Theise ND: Who Classification of Tumours of the Digestive System. Lyon (France): World Health Organization; 2010. p. 281–291.
   Google Scholar
• Edge S, Byrd D, Compton C. Exocrine and endocrine pancreas. Ajcc cancer staging manual. 7th ed. New York, NY: Springer; 2010. p. 241–248.
   Google Scholar
• Collett K, Eide GE, Arnes J, Stefansson IM, Eide J, Braaten A, Aas T, Otte AP, Akslen LA. Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. Clin Cancer Res. 2006;12:1168–1174. doi:10.1158/1078-0432.CCR-05-1533.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Court W, Patterson L, Sanderson S. In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis. Methods Mol Biol. 2009;467:159–181.
   PubMedGoogle Scholar
• Allioli N, Vincent S, Vlaeminck-Guillem V, Decaussin‐Petrucci M, Ragage F, Ruffion A, Samarut J. Tm4sf1, a novel primary androgen receptor target gene over-expressed in human prostate cancer and involved in cell migration. Prostate. 2011;71:1239–1250.
   PubMed Web of Science ®Google Scholar
• Cao J, Yang JC, Ramachandran V, Arumugam T, Deng DF, Li ZS, Xu LM, Logsdon CD. TM4SF1 regulates pancreatic cancer migration and invasion in vitro and in vivo. Cell Physiol Biochem. 2016;39:740–750.
   PubMedGoogle Scholar
• Zheng B, Ohuchida K, Cui L, Zhao M, Shindo K, Fujiwara K, Manabe T, Torata N, Moriyama T, Miyasaka Y, et al. TM4SF1 as a prognostic marker of pancreatic ductal adenocarcinoma is involved in migration and invasion of cancer cells. Int J Oncol. 2015;47:490–498. doi:10.3892/ijo.2015.3022.
   PubMed Web of Science ®Google Scholar
• Sun Y, Xu Y, Xu J, Lu D, Wang J. Role of TM4SF1 in regulating breast cancer cell migration and apoptosis through pi3k/AKT/mtor pathway. Int J Clin Exp Pathol. 2015;8:9081–9088.
   PubMed Web of Science ®Google Scholar
• Cao J, Yang J, Ramachandran V, Arumugam T, Deng D, Li Z, Xu L, Logsdon CD. TM4SF1 promotes gemcitabine resistance of pancreatic cancer in vitro and in vivo. PLoS One. 2015;10:e0144969.
   PubMed Web of Science ®Google Scholar
• Wang P, Bao W, Zhang G, Cui H, Shi G. Transmembrane-4-l-six-family-1, a potential predictor for poor prognosis, overexpressed in human glioma. Neuroreport. 2015;26:455–461.
   PubMed Web of Science ®Google Scholar
• Xue L, Yu X, Jiang X, Deng X, Mao L, Guo L, Fan J, Fan Q, Wang L, Lu S-H, et al. TM4SF1 promotes the self-renewal of esophageal cancer stem-like cells and is regulated by mir-141. Oncotarget. 2017;8:19274–19284. doi:10.18632/oncotarget.13866.
   PubMedGoogle Scholar
• Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559–1564. doi:10.1126/science.1203543.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674. doi:10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70. doi:10.1016/S0092-8674(00)81683-9.
   PubMed Web of Science ®Google Scholar
• Ye X, Weinberg RA. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 2015;25:675–686. doi:10.1016/j.tcb.2015.07.012.
   PubMed Web of Science ®Google Scholar
• Jung HY, Fattet L, Yang J. Molecular pathways: linking tumor microenvironment to epithelial-mesenchymal transition in metastasis. Clin Cancer Res. 2015;21:962–968. doi:10.1158/1078-0432.CCR-13-3173.
   PubMed Web of Science ®Google Scholar
• Visintin A, Knowlton K, Tyminski E, Lin C-I, Zheng X, Marquette K, Jain S, Tchistiakova L, Li D, O’Donnell CJ, et al. Novel anti-TM4SF1 antibody-drug conjugates with activity against tumor cells and tumor vasculature. Mol Cancer Ther. 2015;14:1868–1876. doi:10.1158/1535-7163.MCT-15-0188.
   PubMed Web of Science ®Google Scholar
• Kandel ES, Skeen J, Majewski N, Di Cristofano A, Pandolfi PP, Feliciano CS, Gartel A, Hay N. Activation of AKT/protein kinase b overcomes a g(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol. 2002;22:7831–7841.
   PubMed Web of Science ®Google Scholar
• Song G, Ouyang G, Bao S. The activation of AKT/pkb signaling pathway and cell survival. J Cell Mol Med. 2005;9:59–71. doi:10.1111/jcmm.2005.9.issue-1.
   PubMed Web of Science ®Google Scholar